A peptide analogue of [8-arginine] 
INTRODUCTION
Receptors for the neurohypophyseal peptide hor¬ mone [8-arginine] vasopressin (AVP) were originally classified as V] and V2. These subtypes exhibit different pharmacological profiles and Vi receptors couple to phosphoinositidase C whereas V2 receptors stimulate adenylate cyclase (Michell et al. 1979 ). Subsequently, the availability of synthetic analogues of AVP with defined binding characteristics facili¬ tated further subclassification of AVP isoreceptors as Vla, Vib and V2 (Antoni, 1984; Baertschi & Friedli, 1985; Jard et al. 1986 ). The development of synthetic analogues has also proved invaluable for investigating the physiological and pathophysiological roles of AVP in mammals (Manning et al. 1987a; László et al. 1991) .
It is known that deletion of the C-terminal glycine or glycinamide residue at position 9 drastically reduces the agonist potency of AVP at the Vla vaso¬ pressin receptor (du Vigneaud et al. 1953; Manning et al. 1984) . However, the recent synthesis of a vast number of structural analogues, particularly by Manning et al. (1984 and Sawyer et al. (1988) , has resulted in a range of high affinity ligands which can tolerate the substitution or deletion of Gly or Gly(NH2) at position 9 with little change in antagonist potency.
The availability of heterofunctional ligands (i.e. analogues which recognize Vla receptors selectively and with high affinity, whilst incorporating addi¬ tional functional moieties) would be a great asset to vasopressin receptor research. Potential uses of these ligands include receptor localization, irreversible lig¬ ands and the bases of affinity matrices. This study was to assess the utility of position 9 in the design and synthesis of heterofunctional ligands for the Vla receptor. In this paper we describe the synthesis of a precursor peptide which offers a convenient site of attachment for several functional moieties individu¬ ally or in consort. Moreover, we demonstrate that the heterofunctional ligands produced using this strategy retain high affinity, and pharmacological selectivity, for the Vla vasopressin receptor subtype.
MATERIALS AND METHODS

Materials
[Phe-3,4,5-3H]AVP (53-6 and 67-7 Ci/mmol) and the labelled V]a-selective vasopressin antagonist 4, (Manning et al. 1984, 19876; Sawyer et al. 1988 ) and oxytocin (Elands et al. 1987; Manning et al. 1989 ). These studies demonstrated that the nature of the amino acid residue at position 9 is not critical in determining the affinity of synthetic AVP or oxytocin antagonists. Subsequently, it was estab¬ lished that a dibasic tail domain is sufficient for high affinity binding (Ali et al. 1987 ). These findings were extended by Callahan et al. (1989) Fig. 1 ). When the affinities of ALVP for the V]a receptor and the V2 receptor were determined by competition ligand binding (Fig. 2a and 6 respectively) (Fig. 1) . The structure and purity of the individual analogues were confirmed by a combination of FAB mass spectroscopy, FTIR spectroscopy and analyt¬ ical HPLC (Table 1) .
The binding of the ligands to rat liver Vla receptor (Fig. 2a) and to rat kidney medulla V2 receptor (Fig. 26) (Fig. 1) . Buku et al. (1989) reported that when the Cterminal glycinamide of vasotocin was substituted with iodotyrosine or p-azidophenylalanine there was little effect on its hydro-osmotic activity. However, biotinylphenylalanine at position 9 resulted in a 100-fold decrease in potency (Buku et al. 1989 
